| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
254,036,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$22.93 - $22.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Van Zoonen Marinus Johannes |
Pres., Europe/Intl&Glob. Mkt. |
• – – |
2011-04-01 |
4 |
S |
$23.30 |
$16,380 |
D/D |
(703) |
40,914 |
|
- |
|
| Bain Capital (wc) Netherlands B.v |
10% Owner |
– – • |
2011-03-30 |
4/A |
S |
$22.44 |
$10,459,713 |
I/I |
(466,196) |
25,491,622 |
|
- |
|
| Connaughton John |
Director |
– • • |
2011-03-30 |
4/A |
S |
$22.44 |
$10,459,713 |
I/I |
(466,196) |
25,491,622 |
|
- |
|
| Gilligan Claire A |
Senior V.P. Global Quality |
• – – |
2011-03-30 |
4 |
S |
$23.25 |
$11,904 |
I/I |
(512) |
28,049 |
|
- |
|
| Gilligan Claire A |
Senior V.P. Global Quality |
• – – |
2011-03-30 |
4 |
S |
$23.25 |
$23,971 |
D/D |
(1,031) |
52,375 |
|
- |
|
| Ellman Herman |
Senior V.P., Clinical Devel. |
• – – |
2011-03-30 |
4 |
S |
$23.25 |
$82,445 |
D/D |
(3,546) |
177,049 |
|
- |
|
| Hara Izumi |
Sr. VP, Gen. Counsel & Sec. |
• – – |
2011-03-30 |
4 |
S |
$23.25 |
$86,327 |
D/D |
(3,713) |
184,449 |
|
- |
|
| Herendeen Paul |
Exec. V.P. and CFO |
• – – |
2011-03-30 |
4 |
S |
$23.25 |
$358,190 |
D/D |
(15,406) |
371,712 |
|
- |
|
| Abbrecht Todd M |
Director |
– • – |
2011-03-30 |
4 |
S |
$22.44 |
$10,461,393 |
I/I |
(466,194) |
25,491,622 |
|
- |
|
| Connaughton John |
Director |
– • • |
2011-03-30 |
4 |
S |
$22.44 |
$10,010,987 |
I/I |
(446,196) |
25,511,622 |
|
- |
|
| Bain Capital (wc) Netherlands B.v |
10% Owner |
– – • |
2011-03-30 |
4 |
S |
$22.44 |
$10,010,987 |
I/I |
(446,196) |
25,511,622 |
|
- |
|
| Reichel W Carl |
President, Pharmaceuticals |
• – – |
2011-03-30 |
4 |
S |
$23.25 |
$418,965 |
D/D |
(18,020) |
371,594 |
|
- |
|
| Bruno Anthony D |
Exec. V.P., Corp. Development |
• – – |
2011-03-30 |
4 |
S |
$23.25 |
$391,716 |
D/D |
(16,848) |
308,123 |
|
- |
|
| Jpmp Capital Corp |
10% Owner |
– – • |
2011-03-30 |
4 |
S |
$22.44 |
$20,919,359 |
D/D |
(932,389) |
1,525,195 |
|
- |
|
| J.p. Morgan Partners Global Investors (cayman/sell |
10% Owner |
– – • |
2011-03-30 |
4 |
S |
$22.44 |
$20,919,359 |
D/D |
(932,389) |
1,525,195 |
|
- |
|
| Murray Stephen P |
Director |
– • – |
2011-03-30 |
4 |
S |
$22.44 |
$10,459,668 |
I/I |
(466,194) |
25,491,618 |
|
- |
|
| Connaughton John |
Director |
– • • |
2011-03-16 |
4 |
S |
$22.44 |
$155,253,542 |
I/I |
(6,919,748) |
25,957,818 |
|
- |
|
| Bain Capital (wc) Netherlands B.v |
10% Owner |
– – • |
2011-03-16 |
4 |
S |
$22.44 |
$155,253,542 |
I/I |
(6,919,748) |
25,957,818 |
|
- |
|
| Jpmp Capital Corp |
10% Owner |
– – • |
2011-03-16 |
4 |
S |
$22.44 |
$352,747,861 |
D/D |
(15,722,194) |
1,525,195 |
|
- |
|
| J.p. Morgan Partners Global Investors (cayman/sell |
10% Owner |
– – • |
2011-03-16 |
4 |
S |
$22.44 |
$352,747,861 |
D/D |
(15,722,194) |
1,525,195 |
|
- |
|
| Abbrecht Todd M |
Director |
– • – |
2011-03-16 |
4 |
S |
$23.25 |
$182,778,666 |
I/I |
(7,861,448) |
25,957,816 |
|
- |
|
| Murray Stephen |
Director |
– • – |
2011-03-16 |
4 |
S |
$22.44 |
$176,381,783 |
I/I |
(7,861,447) |
25,957,812 |
|
- |
|
| Hara Izumi |
Sr. VP, Gen. Counsel & Sec. |
• – – |
2011-03-16 |
4 |
S |
$23.25 |
$1,477,096 |
D/D |
(63,531) |
188,162 |
|
- |
|
| Reichel W Carl |
President, Pharmaceuticals |
• – – |
2011-03-16 |
4 |
S |
$23.25 |
$9,300,000 |
D/D |
(400,000) |
389,614 |
|
- |
|
| Ellman Herman |
Senior V.P., Clinical Devel. |
• – – |
2011-03-16 |
4 |
S |
$23.25 |
$1,410,531 |
D/D |
(60,668) |
180,595 |
|
- |
|
380 Records found
|
|
Page 8 of 16 |
|
|
